Association between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer

JAMA

Volumn 307, Issue 4, 2012, Pages 382-390

  Bolton, Kelly L ^a,b   Chenevix Trench, Georgia ^c   Goh, Cindy ^d   Sadetzki, Siegal ^e,f   Ramus, Susan J ^g   Karlan, Beth Y ^h   Lambrechts, Diether ⁱ   Despierre, Evelyn ^j   Barrowdale, Daniel ^k   McGuffog, Lesley ^k   Healey, Sue ^c   Easton, Douglas F ^k   Sinilnikova, Olga ^l,m   Benítez, Javier ^o   García, María J ^n,o   Neuhausen, Susan ^p   Gail, Mitchell H ^a   Hartge, Patricia ^a   Peock, Susan ^k   Frost, Debra ^k   Evans, D Gareth ^q   Eeles, Rosalind ^r   Godwin, Andrew K ^s   Daly, Mary B ^t   Kwong, Ava ^u,w,x   Ma, Edmond S K ^u,v   Lázaro, Conxi ^y   Blanco, Ignacio ^y   Montagna, Marco ^z   D'Andrea, Emma ^z   Nicoletto, Maria Ornella ^z   Johnatty, Sharon E ^c   Kjær, Susanne Krüger ^aa   Jensen, Allan ^aa   Høgdall, Estrid ^aa   Goode, Ellen L ^ab   Fridley, Brooke L ^ab   Loud, Jennifer T ^a   Greene, Mark H ^a   Mai, Phuong L ^a   Chetrit, Angela ^e   Lubin, Flora ^e   Hirsh Yechezkel, Galit ^e   Glendon, Gord ^ac   Andrulis, Irene L ^ac,ad   Toland, Amanda E ^ae   Senter, Leigha ^af   Gore, Martin E ^ag   Gourley, Charlie ^ah   Michie, Caroline O ^ah   Song, Honglin ^ai   Tyrer, Jonathan ^ai   Whittemore, Alice S ^aj   McGuire, Valerie ^aj   Sieh, Weiva ^aj   Kristoffersson, Ulf ^ak   Olsson, Håkan ^ak   Borg, Åke ^ak   Levine, Douglas A ^al   Steele, Linda ^p   Beattie, Mary S ^am,an   Chan, Salina ^am   Nussbaum, Robert L ^am,an   Moysich, Kirsten B ^ao   Gross, Jenny ^h   Cass, Ilana ^h   Walsh, Christine ^h   Li, Andrew J ^h   Leuchter, Ronald ^h   Gordon, Ora ^h   Garcia Closas, Montserrat ^ap   Gayther, Simon A ^g   Chanock, Stephen J ^a   Antoniou, Antonis C ^k   Pharoah, Paul D P ^ai   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l HOSPICES CIVILS DE LYON   (France)

^m UNIVERSITÉ LYON 1   (France)

ⁿ Human Genetics Group   (Spain)

^o Centro Nacional de Investigaciones Oncológicas   (Spain)

^p CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^q CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^t UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^u FOX CHASE CANCER CENTER   (United States)

^v Hong Kong Hereditary Breast Cancer Family Registry   (Hong Kong)

^w HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^x UNIVERSITY OF HONG KONG   (Hong Kong)

^y CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^z VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^aa UNIVERSITY OF COPENHAGEN   (Denmark)

^ab Mayo Clinic   (United States)

^ac CANCER CARE ONTARIO   (Canada)

^ad MOUNT SINAI HOSPITAL   (Canada)

^ae OHIO STATE UNIVERSITY   (United States)

^af THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^ag ROYAL MARSDEN HOSPITAL   (United Kingdom)

^ah UNIVERSITY OF EDINBURGH   (United Kingdom)

^ai UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^aj STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ak LUND UNIVERSITY   (Sweden)

^al MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^am UNIVERSITY OF CALIFORNIA   (United States)

^an UNIVERSITY OF CALIFORNIA   (United States)

^ao ROSWELL PARK CANCER INSTITUTE   (United States)

^ap INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HISTOLOGY; HUMAN; INVASIVE EPITHELIAL OVARIAN CANCER; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 84856158117     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.20     Document Type: Article

References (37)

1. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):353-357.
2. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12): 2807-2816. (Pubitemid 41798292)
3. Soegaard M, Kjær SK, Cox M, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14(12): 3761-3767.
4. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961-967.
5. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10(7):2473-2481. (Pubitemid 38445709)
6. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20-25.
7. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97 (9):2187-2195. (Pubitemid 36444059)
8. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557-1565.
9. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283(17):2260-2265. (Pubitemid 30246777)
10. Buller RE, Shahin MS,Geisler JP, Zogg M, De Young BR, Davis CS. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res. 2002; 8(5):1196-1202. (Pubitemid 34520421)
11. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA; United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res. 1999;59(4):868- 871.
12. Brookmeyer R. Biased sampling of cohorts. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. 2nd ed. New York, NY: John Wiley & Sons; 2005.
13. Tan DS, Rothermundt C, Thomas K, et al. "BRCA-ness"syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008; 26(34):5530-5536.
14. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 2006;5(2):135-142. (Pubitemid 43824469)
15. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245- 251.
16. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; CIMBA. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007;9(2): 104.
17. Pearce CL, Wu AH, Gayther SA, et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer. 2008;98 (2):282-288. (Pubitemid 351161257)
18. Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core: database design, structure, and scope. Hum Mutat. 2000;16(2): 123-131. (Pubitemid 30604901)
19. Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G - >C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186-1200.
20. Buisson M, Anczuków O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68-69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat. 2006;27(10):1024-1029. (Pubitemid 44454055)
21. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet. 2001;27(1):55-58. (Pubitemid 32044518)
22. Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM, Lenoir GMA. A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet. 1998;62(3):713-715. (Pubitemid 28164630)
23. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet. 2002;11(23):2805- 2814. (Pubitemid 35331813)
24. Keiding N. Delayed entry. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Hoboken, NJ: John Wiley & Sons; 2005.
25. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002; 20(9):2310-2318. (Pubitemid 34441658)
26. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90 (15):1138-1145. (Pubitemid 28380718)
27. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000; 66(4):1259-1272. (Pubitemid 30468783)
28. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484-486. (Pubitemid 36432423)
29. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: amutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29(2):218-224. (Pubitemid 40170640)
30. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410-414.
31. Gourley C, Michie CO, Roxburgh P, et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010;28(15):2505- 2511.
32. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008; 8:17.
33. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570-3576.
34. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
35. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol. 2006;101(3):403-410. (Pubitemid 43729975)
36. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
37. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15): 2512-2519.